Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of Rimeporide in Patients With Duchenne Muscular Dystrophy
Conditions
Interventions
Rimeporide
Locations
4
France
I-Motion - Hôpital Armand Trousseau
Paris, Île-de-France Region, France
San Raffaele Hospital
Milan, Italy
Santa Creu i Sant Pau Hospital
Barcelona, Spain
UCL Institute of Child Health and Great Ormond Street Hospital
London, United Kingdom
Start Date
March 1, 2016
Primary Completion Date
December 1, 2017
Completion Date
February 1, 2018
Last Updated
July 18, 2019
NCT03992430
NCT05429372
NCT03963453
NCT03769116
NCT03675126
NCT05688072
Lead Sponsor
EspeRare Foundation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions